Morgan Stanley Boosts Personalis (NASDAQ:PSNL) Price Target to $13.00

Personalis (NASDAQ:PSNL) had its target price upped by investment analysts at Morgan Stanley from $9.00 to $13.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s target price would suggest a potential downside of 12.54% from the company’s previous close.

Several other research firms have also recently commented on PSNL. BTIG Research cut their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Personalis Trading Up 5.3%

PSNL traded up $0.75 on Thursday, hitting $14.86. 3,137,133 shares of the company’s stock were exchanged, compared to its average volume of 2,184,370. Personalis has a fifty-two week low of $3.84 and a fifty-two week high of $15.36. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -14.63 and a beta of 2.24. The firm has a 50-day moving average price of $9.62 and a 200-day moving average price of $8.57.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.48 million. On average, equities analysts predict that Personalis will post -1.06 EPS for the current year.

Insider Activity at Personalis

In other news, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 335,032 shares of company stock valued at $4,091,929 over the last quarter. 4.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its position in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Personalis by 4.5% during the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares during the period. Royal Bank of Canada increased its holdings in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the last quarter. Howland Capital Management LLC raised its position in Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after purchasing an additional 2,500 shares during the period. Finally, Intech Investment Management LLC lifted its stake in Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after purchasing an additional 3,851 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.